Teleflex lowers 2026 GAAP revenue growth outlook to 13.4%-14.4%
Company cuts 2026 GAAP EPS guidance to $2.54-$2.84
Teleflex raises 2026 adjusted diluted EPS outlook to $6.90-$7.20
Overview
U.S. medical technologies provider's Q2 revenue rose 29% yr/yr, beating analyst expectations
Adjusted EPS from continuing operations rose to $1.76 from $1.73 a year ago
Company completed OEM business sale, repaid debt, and repurchased $250 mln in stock
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$570.30 mln
$559.60 mln (13 Analysts)
Q2 Adjusted EPS continuing operations
$1.76
Q2 EPS continuing operations
$0.96
Result drivers and analyst coverage
Vascular and surgical growth - Co said revenue growth was led by strong performance in its Vascular and Surgical businesses
Integration delays - Co said integration of the acquired Biotronik Vascular Intervention business is taking longer than expected, affecting revenue outlook
Innovation pipeline - Co highlighted FDA approval for EZPLAZ and progress in the Freesolve clinical program as milestones in its innovation pipeline
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Teleflex Incorporated is $145.00, about 6% above its August 5 closing price of $136.78
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 16 three months ago
TFX•
